Non-Hodgkin Lymphoma

Study shows long-term responses in non-Hodgkin patients treated with Zevalin

Published in Cancer Weekly, January 4th, 2005

Research presented at the American Society of Hematology 46th Annual Meeting (ASH) indicates that Zevalin (ibritumomab tiuxetan) frequently produces durable long-term responses in patients with relapsed or refractory B-cell NHL. These data show that in patients who respond to Zevalin, a monoclonal antibody, the median duration of response is 52 months.

Patients whose cancer did not progress until after 12 months were considered to have a long-term response. A high proportion of these patients was older than 60 years and had received at least 3 prior therapies for their disease. Long-term responses were achieved in 37% of all patients and 39% of patients with follicular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-01-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry